PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Sandoz abandoning US development of Rixathon to focus on more lucrative markets will benefit the company in the long term, says GlobalData

Novartis’ Sandoz division recently announced that it was no longer pursuing US approval for Rixathon, its biosimilar version of Roche’s Rituxan/MabThera (rituximab). Despite the fact that not seeking approval in the US is a lost opportunity in the short term, Sandoz’s strategy to prioritize other more profitable markets for Rixathon will benefit the company in the long term, says GlobalData, a leading data and analytics company.
Rixathon is already approved in the EU, Japan, Switzerland, and Australia, but Sandoz received a complete response letter from the US regulatory body in May 2018. Although the company’s initial plans were to conduct further discussions with the FDA to bring the biosimilar to the US market as soon as possible, Sandoz has now decided to abandon development in this market.
Chloé Thépaut, MRes, Senior Pharma Analyst at GlobalData, comments: “The US is lagging behind other markets for biosimilar development, with only 14 approved products to date versus 61 in the EU. Sandoz’s choice to stop Rixathon development in this market highlights the fact that, even for major players, the US market is not a priority for biosimilars.”
Sandoz’s decision was partially due to existing competition from other biosimilar developers like Celltrion for a share of Rituxan’s sales. Celltrion is likely to gain the coveted first-to-market advantage, as it announced in October 2018 that the FDA Oncologic Drugs Advisory Committee unanimously backed its rituximab biosimilar, Truxima.
Thépaut continues: “Further delays before a potential approval for Rixathon would mean that Sandoz would have too much catching up to do before stealing any meaningful market share from Truxima. However, Sandoz is keeping its options open by shifting its focus to other markets for opportunities for Rixathon, and looking to develop other biosimilar products in the US.”
Although biosimilar development in the US has sped up in recent years, with five products being approved in the past 10 months, significant challenges remain for biosimilar developers in this market.
US key opinion leaders (KOLs) interviewed for GlobalData’s report: ‘Hot Topic Report: Biosimilars in Oncology’ stated that they still had doubts surrounding the equivalence of biosimilar products to biologic originator products, and that this would negatively impact biosimilar uptake. Additionally, current discounts have been deemed insufficient by KOLs, some of whom noted that the cost of switching patients from biologic originator products to biosimilars is greater than the cost that is saved by using biosimilars.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026